公开(公告)号：US07801599B2

公开(公告)日：2010-09-21

申请号：US11556413

申请日：2006-11-03

申请人： Wendy A. Young ,  Michel J. Cormier

发明人： Wendy A. Young ,  Michel J. Cormier

IPC分类号： A61N1/30

CPC分类号： A61N1/30

摘要： A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided.

摘要翻译： 具有电连接到阳极和阴极的阳极，阴极和电源的透皮电运输药物递送装置。 阳极和阴极中的至少一个包括电极和由包含聚合物材料的外壳和与外壳接触的水性介质的容器。 水性介质包括（i）药物或电解质盐或其混合物，（ii）丙二醇，和（iii）足以抑制水性介质中微生物生长的量的抗微生物剂。 丙二醇防止抗微生物剂被用于构建输送装置的其它材料吸附。 还提供了一种制备透皮电转运药物递送装置的方法。

公开(公告)号：US5120545A

公开(公告)日：1992-06-09

申请号：US562788

申请日：1990-08-03

申请人： Philip W. Ledger ,  Michel J. Cormier ,  Alfred Amkraut

发明人： Philip W. Ledger ,  Michel J. Cormier ,  Alfred Amkraut

IPC分类号： A61K9/70 ,  A61K33/02

CPC分类号： A61K9/0009 ,  A61K33/02 ,  A61K9/7084

摘要： The present invention is directed to a method of reducing or preventing skin sensitization by inhibiting the immunological processing of a sensitizing drug as an antigen. The drug is sensitizing to humans, i.e., the drug is susceptible to inducing skin or mucosa sensitization in a human when the drug is transdermally administered to the human at a therapeutically effective rate. Skin sensitization reduction or prevention is induced by coadministering to the skin or mucosa of the human:(a) a therapeutically effective amount of a sensitizing drug, at a therapeutically effective rate over a predetermined period of time; and(b) an antigen processing-inhibiting agent in an amount effective to inhibit the antigen processing of the drug.The system of the invention comprises a matrix adapted to be placed in sensitizing drug and antigen processing-inhibiting agent transmitting relation to the selected skin or mucosa site. The matrix contains sufficient amounts of the drug and the agent to continuously coadminister to the skin or mucosa site the drug, at a therapeutically effective rate and over a predetermined delivery period, and the antigen processing-inhibiting agent, at a rate and for a period of time sufficient to inhibit the processing of the drug as an antigen.

摘要翻译： 本发明涉及通过抑制作为抗原的敏化药物的免疫处理来减少或预防皮肤致敏的方法。 药物对人类敏感，即当药物以治疗有效的速率经皮给药时，药物易于引起人类皮肤或粘膜致敏。 通过向人的皮肤或粘膜共同诱导皮肤致敏减少或预防：（a）治疗有效量的敏化药物，以预定时间段的治疗有效速率; 和（b）有效抑制药物抗原加工的抗原加工抑制剂。 本发明的系统包括适于放置在致敏药物和抗原加工抑制剂中的基质，其与所选择的皮肤或粘膜部位传递关系。 基质含有足够量的药物和药剂，以治疗有效速率和超过预定的递送期间，以一定的速率和一段时间连续地连续地附着到皮肤或粘膜部位，药物，抗原加工抑制剂 的时间足以抑制作为抗原的药物的加工。